Mistral Pharma Inc.

Mistral Pharma Inc.

October 12, 2005 08:48 ET

Mistral Pharma Submits a Provisional Patent Application for MIST-B01

MONTREAL, QUEBEC--(CCNMatthews - Oct. 12, 2005) - Mistral Pharma Inc. (TSX VENTURE:MIP) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its MIST-B01 product. Mistral has recently announced positive clinical pharmacokinetic results on MIST-B01, a new once-daily formulation of a drug which is usually prescribed twice-daily. This patent application was filed by the Montreal office of Bereskin & Parr, a leading patent agent firm.

"This patent application is a first step in our intellectual property strategy for MIST-B01, our lead product in development" said Mr. Bertrand F. Bolduc, Mistral's President & CEO. "With this patent application filed and our recent clinical results, Mistral is well positioned to begin discussions with a potential commercial partner" he added.

About Bereskin & Parr

Bereskin & Parr is a leading Canadian intellectual property law firm and serves clients in over 100 countries worldwide. With its 200 people, including more than 60 lawyers, patent and trade mark agents, and technical consultants, Bereskin & Parr is consistently rated in Canada as the market benchmark for intellectual property law. Bereskin & Parr was founded in 1965, and has offices in Toronto, Mississauga, Waterloo and Montreal. www.bereskinparr.com

About Mistral Pharma Inc.

Mistral Pharma is an emerging oral drug delivery company which develops generic and branded controlled-delivery products using its PROCISE™, SAVIT™ and CHRONOP™ geometry surface area technologies. These technologies offer many competitive advantages including flexible and fast development, competitive cost of goods and the use of "generally recognized as safe" excipients. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    (514) 920-0909 # 24
    Mistral Pharma Inc.
    Alain Provencher, CA
    Vice-president, Finance & Chief Financial Officer
    (514) 920-0909 # 22